Treatment of Hodgkin’s disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) courses without radiotherapy

van den Berg, H.; Stuve, W.; Behrendt, H.

Published in:
Medical and Pediatric Oncology

DOI:
10.1002/(SICI)1096-911X(199707)29:1<23::AID-MPO4>3.0.CO;2-U

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Treatment of Hodgkin’s Disease in Children With Alternating Mechlorethamine, Vincristine, Procarbazine, and Prednisone (MOPP) and Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Courses Without Radiotherapy

Henk van den Berg, MD, PhD,* Wouter Stuve, MB, and Henk Behrendt, MD, PhD

Since the introduction of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy, children with Hodgkin’s disease (HD) have been treated with chemotherapy alone. The occurrence of side effects related to irradiation (especially secondary solid tumors) is less likely to occur. Alkylating agents in the MOPP chemotherapy combinations are, however, known for their late effects, i.e., gonadal dysfunction and secondary malignancies. Combination with non-alkylating and non-cross-resistant drugs (as in the adriamycin, bleomycin, vinblastine, and dacarbazine [ABVD] combination) may give superior treatment results and possibly a decrease in the occurrence of side effects.

From 1988 to 1993 all children presenting with HD were treated with alternating MOPP and ABVD courses (3 × MOPP, 3 × ABVD). Twenty-one children (7 females, 14 males), ages 5–18 years (median 14 years) were included; their clinical stages were I, 7 patients; II, 8 patients; III, 5 patients; IV, 1 patient. Their pathology revealed 2 lymphocytic predominance, 17 nodular sclerosis, 1 mixed cellularity. In 1 patient only cytology was done and thus histopathologic subclassification was not possible. Two children have relapsed; disease-free survival is 90%. Analysis of toxicity revealed no decrease in cardiac function by ultrasound examination and no pulmonary effects noted by carbon monoxide diffusion. In 1 of the 10 children tested, mild hypogonadism was noted. No secondary tumors occurred.

From this small population of children with HD we conclude that treatment with MOPP/ABVD for 6 cycles without radiotherapy may be adequate. The occurrence of gonadal dysfunction may be less frequent than with 6 cycles of MOPP. However, more patients and further follow-up are needed. Med. Pediatr. Oncol. 29:23–27, 1997. © 1997 Wiley-Liss, Inc.

Key words: Hodgkin’s disease; children; chemotherapy; radiotherapy; gonadal function; cardiac function; secondary malignancies; pulmonary function

INTRODUCTION

From 1970 to 1975 we treated children with stage I and stage II Hodgkin’s disease (HD) with extended field irradiation (EF) to a dose of 40 Gy. Patients with stage III and stage IV HD received mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) in combination with irradiation. The occurrence of severe sequelae, including a diminished growth of soft tissue and bone, aseptic bone necrosis [1], hypothyroidism [2], gonadal dysfunction [3,4] and secondary malignancies [5,6] stimulated us to search for other treatment regimens. In 1975 we changed our policy. Children with HD were treated with 6 MOPP courses only. Although in those with bulky disease, with a tumor diameter more than 4 cm, radiotherapy (25 Gy involved field irradiation) was added. Disease-free survival rates for patients with non-bulky and bulky disease were 90 and 87.5%, respectively [7]. It should be emphasized that only some of the serious sequelae noted are associated with irradiation. The alkylating agents used in HD also have similar effects with respect to secondary tumor induction and reproductive capacity [8–10]. Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) course was introduced to improve cure without increasing toxicity associated with MOPP [11,12]. For this reason, we used from 1984 to 1987 6 courses of ABVD without radiotherapy for all children with HD. This, however, resulted in 5 relapses of 17 cases [13]. We found the number of relapses too high to be acceptable and stopped this treatment. From 1988 children suffering from HD were treated with alternating courses of MOPP and ABVD.

© 1997 Wiley-Liss, Inc.
PATIENTS AND METHODS

From 1988 to 1993, 21 children presenting with HD at our institution were included in this study. Pretreatment evaluation consisted of a detailed patient history, physical examination, histologic examination of the involved lymph node, complete blood count, urinalysis, liver function tests, serum uric acid, chest X-ray, bone marrow aspiration and biopsy, and abdominal ultrasound examination. None of the children underwent laparotomy with splenectomy. Clinical stage was determined according to the Ann Arbor recommendations [14]. The treatment given consisted of 3 modified ABVD courses and 3 MOPP courses; each ABVD course was followed by a MOPP course (see Table I). To decrease the risk of lung toxicity, bleomycin was not given as intravenous bolus injection, but was given by 6-hr infusion. In none of the patients cytokines were used. Supportive care measures were stable throughout the study. During treatment pulmonary carbon monoxide diffusion (COD) was measured prior to every ABVD administration and at the completion of therapy. Echocardiography was done prior to and at the end of therapy.

For the calculation of survival data a Cox-Mantel test was used. For comparisons of toxicity data a Wilcoxon test was applied.

RESULTS

Seven girls and 14 boys were included in this study. Ages at diagnosis ranged from 5 to 18 years (median 14 years). The relation between clinical stage (CS) and pathologic findings is shown in Table II. The distribution of CS and histopathology is similar to other literature reports [15–19]. In one patient no histopathologic subtype was available, as the diagnosis of HD was made on cytologic criteria. Seven patients were staged as CS I, 8 patients as CS II, 5 patients as CS III, and 1 patient as CS IV. Event-free survival was 90% (SE ± 7.7). Disease-free survival (DFS) was 90% (SE ± 6.22); follow-up interval was 14–82 months (median 61 months) (Figs. 1, 2). Two children suffered a relapse. Clinical data on the relapsed patients are shown in Table III. In one additional child mediastinal widening persisted throughout the treatment. As this suggested persistent disease, irradiation of the area was added, but the radiographs did not change. Surgical removal revealed a benign thymic cyst and there was no evidence of HD. None of the 21 children died from toxic or infectious complications.

Toxicity

Cardiac toxicity. Left ventricle shortening data (pretreatment as well as posttreatment) from 15 patients were available. In one child the shortening fraction could not be calculated due to pretreatment pericardial effusion. From the others pretreatment values ranged from 25 to 52%, with a median value of 37% (normal values 29–41%). After completion of therapy the shortening fractions ranged between 32 and 43% (median value 37%). The differences were not statistically significant.

Pulmonary toxicity. COD data taken at the start and at the end of treatment were available in 16 children. At the time of diagnosis, COD values ranged from 63 to 120% (median 87%) compared to mean control values. After completion of therapy the shortening fractions ranged between 32 and 43% (median value 37%). The differences were not statistically significant.

Gonadal and thyroid toxicity. Of the patients who reached adolescence, luteinizing hormone (LH) and follicle stimulating hormone (FSH) values were measured in 10 cases. Six patients were found to have normal levels of both hormones (<15 mU/l). In one 16-year-old girl, a slight increase of LH was observed (19.5 mU/l), but the FSH was normal (11 mU/l), and her menstrual cycle was normal. One patient at age 18 years had a normal LH (9.0 mU/l), a slightly increased FSH (19.0 mU/l), and a low testosterone value (2.2 nmol/l). His physical examination

<table>
<thead>
<tr>
<th>Combination</th>
<th>Dose (mg/m$^2$)</th>
<th>Days of treatment</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABVD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adriamycin i.v.</td>
<td>25</td>
<td>1 and 14</td>
<td></td>
</tr>
<tr>
<td>Bleomycin i.v.</td>
<td>6</td>
<td>1 and 14</td>
<td></td>
</tr>
<tr>
<td>Vinblastine i.v.</td>
<td>6</td>
<td>1 and 14</td>
<td></td>
</tr>
<tr>
<td>Dacarbazine i.v.</td>
<td>250</td>
<td>1 and 14</td>
<td></td>
</tr>
<tr>
<td>MOPP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechlorethamine i.v.</td>
<td>6</td>
<td>28 and 35</td>
<td></td>
</tr>
<tr>
<td>Vincristine i.v.</td>
<td>1.5</td>
<td>28 and 35</td>
<td></td>
</tr>
<tr>
<td>Procarbazine p.o.</td>
<td>80</td>
<td>28–42</td>
<td></td>
</tr>
<tr>
<td>Prednisone p.o.</td>
<td>40</td>
<td>28–42</td>
<td></td>
</tr>
</tbody>
</table>

*These consecutive courses were repeated 3 times. i.v., intravenously; p.o., orally.

<table>
<thead>
<tr>
<th>CS</th>
<th>LP</th>
<th>NS</th>
<th>MC</th>
<th>LD</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A</td>
<td>2</td>
<td>4</td>
<td>—</td>
<td>6</td>
</tr>
<tr>
<td>II</td>
<td>B</td>
<td>—</td>
<td>1</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>III</td>
<td>A</td>
<td>—</td>
<td>4</td>
<td>—</td>
<td>4</td>
</tr>
<tr>
<td>IV</td>
<td>B</td>
<td>—</td>
<td>3</td>
<td>1</td>
<td>4</td>
</tr>
</tbody>
</table>

*CS, clinical stage; LP, lymphocytic predominance; NS, nodular sclerosis; MC, mixed cellularity; LD, lymphocytic depletion.

*One patient with only cytologic data.
revealed delayed puberty. Another boy, the one who re-
ceived mediastinal radiation plus chemotherapy, showed
an increase of LH and FSH values of 20 and 18 mU/l and
a testosterone value of 9.0 nmol/l. His thyroid function
revealed mild hypothyroidism with a thyroxine of 65
nmol/l, T3 of 1.7 nmol/l, Free-T4 of 11.1 pmol/l, and
thyroid stimulating hormone (TSH) of 4.2 mE/l. He has
not yet begun hormone replacement therapy. None of the
boys has submitted semen analysis yet. None of the girls
has given birth to a child and none of the boys has fa-
thered a child.

Secondary tumors. No secondary malignancies have
been noted in this population.

DISCUSSION

Since the addition of MOPP chemotherapy to EF com-
bined therapy has become standard treatment for HD in
most centers [15,19,20]. Ziegler et al. [21] reported sur-
vival rates of 65% in CS I and CS II children following
MOPP chemotherapy alone. Olweny et al. [6] later up-
dated these data and reported survival rates of 75% and
60% for early and late stage patients, respectively. We
reported in 1987 that in children with non-bulky disease,
i.e., lymph nodes <4 cm, chemotherapy alone resulted in
a DFS of 90%. Those experiencing a relapse were sal-
vaged with additional chemotherapy [7]. Ekert et al. [22]
reported DFS rates of 92% for patients with all stages of
disease using chemotherapy only. Sackman-Muriel et al.
[23] concluded from a randomized study that comparable
results can be achieved using chemotherapy with or with-
out radiotherapy. Recently, Lobo-Sanahuja et al. [16]
reported on 86 children with DFS rates of 90% and 60%
for CS I–IIIA and CS IIIB–IV, treated with chemo-
therapy only. In most studies, however, only a few CS IV
patients have been included. In a retrospective analysis,
Bader et al. [24] showed that freedom from progression
improved only in CS IVB patients receiving combined
therapy compared to those treated with chemotherapy
only. Our study indicates that ABVD/MOPP alone gives
an acceptable survival rate, but the number of patients in
our study is too small to make a reliable comparison with
treatment including radiotherapy.

Using MOPP chemotherapy many long-term prob-
lems have been reported. In particular, the alkylating
agents mechlorethamine and procarbazine are associated
with gonadal dysfunction and secondary malignan-
cies [5,6,10]. The hypothesis that the highest probability of
cure can be achieved using non-cross-resistant drugs [25]
and the reported long-term effects using MOPP led to the
introduction of ABVD [26]. Santoro et al. [27] described
good results (92% DFS) using ABVD courses in combi-
nation with radiotherapy [12]. This treatment, however,
is associated with parenchymal lung damage and fibrosis
[12,27]. Gonadal toxicity appears to be lower following
ABVD compared with MOPP [11]. The occurrence of secondary malignancies following MOPP or ABVD in combination with radiotherapy is probably similar [28]. The occurrence of secondary leukemias is estimated at 11% at 10 years and is probably related to the cumulative dose of alkylating agents [29]. Fewer cases of acute myeloid leukemia (AML) and non-Hodgkin’s lymphoma are noted in ABVD-treated patients compared to MOPP-treated patients [11,30]. The occurrence of solid tumors seems related to the radiotherapy. In pediatric patients, results with ABVD/MOPP in combination with low dose radiotherapy are quite acceptable in these respects [19,31]. Instead of reducing irradiation we followed another strategy. Initially we treated patients with MOPP alone [7]. In an attempt to decrease toxicity, we switched our therapy to ABVD courses without radiotherapy. The results were less favorable [13]. As it has been reported that gonadal damage may be reversible after only 3 cycles of MOPP, we then changed our policy to the present protocol [32]. However, there are no data currently available on ABVD/MOPP-treated patients who were not also irradiated. Our results indicate that this treatment modality is feasible with a short-term EFS of 90% in a small number of patients. However, when a relapse occurs, the outcome, as based on our two observations, is poor. The decrease in DFS in patients with more advanced stage HD treated without radiotherapy as reported by Lobo-Sanahuja et al. [16] using CVPP (cyclophosphamide, vinblastine, procarbazine, prednisone)/EBO (epirubicin, bleomycin, and vincristine) has not been seen in our patients, but as only one of our patients was CS IV, we cannot make a conclusion for this category of patients.

In our study to date only one child with initially CS I and another child with CS II have relapsed. One wonders if pathologic staging would have improved these results. We did not perform laparotomy with splenectomy, as overwhelming postsplenectomy sepsisemia and bowel obstruction are serious complications [33,34]. A major bias in our cohort due to an artificially low number of patients with high stages of HD by omitting laparotomy is not likely considering the data of Pao and Kun [35]. In 201 children they showed that 1 of 32 cases with CS I and 25 of 123 cases with CS II were upstaged to stage III after laparotomy; on the other hand, their data showed downstaging in about half of the children with CS III [35].

Complications due to the use of bleomycin and adriamycin treatment could not be demonstrated by ultrasound examination of the heart and COD, although follow-up is short and these may not be the most sensitive tests to use. Comparison with other reports considering pulmonary function are favorable, however, our group is too small to draw firm conclusions. Late effects may become evident at longer follow-up. Anthracyclin-related severe sequelae, even in low dosages, are well known [36]. Our preliminary data on gonadal function are encouraging, although in several patients this cannot be assessed as they did not reach puberty yet. Nine of the 10 patients have normal endocrine function by laboratory tests. In one patient increased gonadotropie hormones may possibly indicate gonadal dysfunction. Thyroid function was also decreased in this patient. This was, however, the only child who received radiotherapy for what proved to be a thymic cyst. It should be emphasized that reproductive capacity can ultimately only be ascertained by a pregnancy. Although boys were offered semen analysis, many adolescent patients are reluctant to proceed with this testing. No statement can be made to the incidence of secondary solid tumors, which occur more than 10 years following treatment [29,33].

We conclude that 6 cycles ABVD/MOPP treatment without radiotherapy gives a high cure rate in our patients with HD and short-term side effects seem low. However, larger studies are needed to confirm these findings.

REFERENCES

13. Behrendt H, Brinkhuis M, Van Leeuwen EF: Treatment of child-